The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Amphetamine Decreases 2C-Adrenoceptor Binding of [11C]ORM-13070: A PET Study in the Primate Brain
Open accessAbstract
BACKGROUND: The neurotransmitter norepinephrine has been implicated in psychiatric and neurodegenerative disorders. Examination of synaptic norepinephrine concentrations in the living brain may be possible with positron emission tomography (PET), but has been hampered by the lack of suitable radioligands. METHODS: We explored the use of the novel α2C-adrenoceptor antagonist PET tracer [(11)C]ORM-13070 for measurement of amphetamine-induced changes in synaptic norepinephrine. The effect of amphetamine on [(11)C]ORM-13070 binding was evaluated ex vivo in rat brain sections and in vivo with PET imaging in monkeys. RESULTS: Microdialysis experiments confirmed amphetamine-induced elevations in rat striatal norepinephrine and dopamine concentrations. Regional [(11)C]ORM-13070 receptor binding was high in the striatum and low in the cerebellum. After injection of [(11)C]ORM-13070 in rats, mean striatal specific binding ratios, determined using cerebellum as a reference region, were 1.4±0.3 after vehicle pretreatment and 1.2±0.2 after amphetamine administration (0.3mg/kg, subcutaneous). Injection of [(11)C]ORM-13070 in non-human primates resulted in mean striatal binding potential (BP ND) estimates of 0.65±0.12 at baseline. Intravenous administration of amphetamine (0.5 and 1.0mg/kg, i.v.) reduced BP ND values by 31-50%. Amphetamine (0.3mg/kg, subcutaneous) increased extracellular norepinephrine (by 400%) and dopamine (by 270%) in rat striata. CONCLUSIONS: Together, these results indicate that [(11)C]ORM-13070 may be a useful tool for evaluation of synaptic norepinephrine concentrations in vivo. Future studies are required to further understand a potential contribution of dopamine to the amphetamine-induced effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Representative whole-hemisphere autoradiograms showing the distribution of [11C]ORM-13070 binding to sagittal sections of a monkey brain (A), coronal sections of a human brain (B), and coronal sections of two rat brains (C). The rat sections were obtained from animals euthanized 30min post [11C]ORM-13070 injection. Amphetamine (‘Amph’, 0.3mg/kg subcutaneous [s.c.], 20min before i.v. injection of [11C]ORM-13070) tended to reduce the specific binding ratios (mean ± standard deviation, n = 5) in the olfactory tubercle (OT) and striatum (STR) of rats (D). In the primate brain sections, specific binding was demonstrated by co-incubation with a 10 µM concentration of the subtype non-selective α2-adrenoceptor antagonist atipamezole. SBR, specific binding ratio.](https://figures.cochat.ai/paper-figures/16c8154c0bdc45b294a54ca96af0b06b/amphetamine-decreases-2c-adrenoceptor-binding-of-11c-orm-13070-a-pet-study-in-figure-1.jpg)
![Figure 2. Evaluation of the utility of [11C]ORM-13070 as a positron emission tomography (PET) tracer in cynomolgus monkeys. (A) PET summation images represent mean radioactivity levels in time frames of 9–63min after injection of [11C]ORM-13070. (B) Mean regional brain radioactivity in the striatum (■) and cerebellum (▲) during baseline conditions (mean ± standard deviation, n = 9). (C) Correlation between striatal BP ND (simplified reference tissue model [SRTM], 33min) and mean striatal binding potential (BP ND) estimates calculated by SRTM (63min) and interval method (IM) (n = 20). (D) Radiochromatogram of a plasma sample obtained 30min after i.v. injection of [11C]ORM-13070. SUV, standard uptake value.](https://figures.cochat.ai/paper-figures/906b73eb1b854a67999d699a67aa29d5/amphetamine-decreases-2c-adrenoceptor-binding-of-11c-orm-13070-a-pet-study-in-figure-2.jpg)
![Figure 3. (A) Time activity course for regional radioactivity (SUV) in the striatum and cerebellum during baseline and pretreatment with atipamezole (500 µg/kg) before i.v. injection of [11C]ORM-13070 in a representative cynomolgus monkey. (B) Relative decrease in mean striatal binding potential as a function of atipamezole dose and atipamezole concentration in plasma. The lines represent a constrained one-site binding fit.](https://figures.cochat.ai/paper-figures/60f2a8902fcb4f6d8b0c48c805ec901e/amphetamine-decreases-2c-adrenoceptor-binding-of-11c-orm-13070-a-pet-study-in-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary pharmacologic effect of both amphetamine and methylphenidate is to increase central dopamine and norepinephrine activity, which impacts executive and attentional function.”
From The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities (2018) · cites this paper as [59]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The main mechanism of action of AMP is to increase synaptic extracellular DA and NE levels (44, 52, 59, 60, 67, 68, 71, 78, 80, 85, 87, 94, 105, 107, 128).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021 · cited 2×
“BPND estimates were calculated with the simplified reference tissue model (SRTM; with time interval 0–33 min; Lammertsma and Hume, 1996) and the interval method (with time interval of 4–33 min; Ito et al.”
MethodLaruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291 · cited 2×
“…of synaptic DA in drug actions (Tiihonen et al., 1996; Brody et al., 2004), in normal neuropsychology (see for review Egerton et al., 2009), as well as in the pathophysiology of addiction (Volkow et al., 1997), schizophrenia (Laruelle et al., 1996), and Parkinson’s disease (Piccini et al., 2003).”
BackgroundMechanisms of neurotransmitter release by amphetamines: A review
Sulzer, D., Sonders, M. S., Poulsen, N. W., & Galli, A. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.003 · Cited by 1,209
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · cited 1×
“In the 1990s, it was already demonstrated that receptor binding of dopamine (DA) D2 receptor radioligands can be reduced by 10–30% by amphetamine-induced elevations of synaptic DA concentrations in human subjects (Laruelle et al., 1995; Breier et al., 1997).”
BackgroundBymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123 · cited 1×
“Administration of atomoxetine to freely-moving rats increased striatal extracellular NE concentrations almost two-fold, without significant effects on DA, which agrees with previous results (Bymaster et al., 2002).”
ResultImaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review
Laruelle, M. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200003000-00001 · Cited by 944 · cited 1×
“PET measurements, combined with amphetamine administration, have previously been used to investigate changes in synaptic DA concentrations in humans (Laruelle, 2000).”
MethodDecreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects
Volkow, N. D., Wang, G.-J., Fowler, J. S., Logan, J., Gatley, S. J., Hitzemann, R., Chen, A. D., Dewey, S. L., & Pappas, N. (1997) · Nature · doi:10.1038/386830a0 · Cited by 854 · cited 1×
“, 2009), as well as in the pathophysiology of addiction (Volkow et al., 1997), schizophrenia (Laruelle et al.”
Distribution of α2-adrenergic receptor subtype gene expression in rat brain
Scheinin, M., Lomasney, J. W., Hayden-Hixson, D. M., Schambra, U. B., Caron, M. G., Lefkowitz, R. J., & Fremeau, R. T. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90386-7 · Cited by 430
Self-citationSmoking-Induced Ventral Striatum Dopamine Release
Brody, A. L., Olmstead, R. E., London, E. D., Farahi, J., Meyer, J. H., Grossman, P., Lee, G. S., Huang, J., Hahn, E. L., & Mandelkern, M. A. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.7.1211 · Cited by 347 · cited 1×
“This application of PET has provided an important understanding of the role of synaptic DA in drug actions (Tiihonen et al., 1996; Brody et al., 2004), in normal neuropsychology (see for review Egerton et al.”
Background
Research works printed but not linked: 3
- Jakobsen, 2006, Journal of Nuclear Medicine, 47, 2008
- Laruelle, 1995, Journal of Nuclear Medicine, 36, 1182
- Marasini, 1991, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies, 29, 111
Cited by
Faraone, S. V. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.001 · Cited by 631
“The main mechanism of action of AMP is to increase synaptic ex- tracellular DA and NE levels (Avelar et al., 2013; Covey et al., 2013; Finnema et al., 2015; Floor and Meng, 1996; Jedema et al., 2014; Joyce et al., 2007; Kuczenski and Segal, 1997; May et al., 1988; Mukherjee et al., 1997; Pum et…”
InfluentialChristiansen, L., Beck, M. M., Bilenberg, N., Wienecke, J., Astrup, A. V., & Lundbye‐Jensen, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060841 · Cited by 190
Application of cross-species PET imaging to assess neurotransmitter release in brain
Finnema, S. J., Scheinin, M., Shahid, M., Lehto, J., Borroni, E., Bang‐Andersen, B., Sallinen, J., Wong, E. H. F., Farde, L., Halldin, C., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3938-6 · Cited by 88
Self-citationUys, M. M., Shahid, M., & Harvey, B. H. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00144 · Cited by 90
Quantitative positron emission tomography in brain research
Heurling, K., Leuzy, A., Jonasson, M., Frick, A., Zimmer, E. R., Nordberg, A. K., & Lubberink, M. (2017) · Brain Research · doi:10.1016/j.brainres.2017.06.022 · Cited by 63
Metadata
- Authors
- Finnema, S. J., Hughes, Z. A., Haaparanta-Solin, M., Stepanov, V., Nakao, R., Varnas, K., Varrone, A., Arponen, E., Marjamaki, P., Pohjanoksa, K., Vuorilehto, L., Babalola, P. A., Solin, O., Grimwood, S., Sallinen, J., Farde, L., Scheinin, M., & Halldin, C.
- Affiliations
- University of Turku (FI)
- Corresponding author
- Scheinin, M.
- Halldin, C.
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-12-13
- Volume
- 18
- Issue
- 3
- Pages
- pyu081-pyu081
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4360244
- OpenAlex
- W1758995111
- Cited by
- 17
- References
- 48
- Citations by year
- 2024: 2 · 2023: 1 · 2022: 1 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 3 · 2016: 1 · 2015: 2
- FWCI
- 0.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- European Federation of Pharmaceutical Industries and Associations
- European Commission (FP7/2007, 115008)
- Innovative Medicines Initiative
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- amphetamine, alpha2C-adrenoceptor, dopamine, striatum, PET radiotracer, microdialysis, non-human primates
- MeSH terms
- Atomoxetine Hydrochloride, Amphetamine, Central Nervous System Stimulants, Animals, Brain, Dioxanes, Female, Humans, Imidazoles, Macaca fascicularis, Male, Piperazines, Propylamines, Protein Binding, Time Factors, Rats, Sprague-Dawley, Receptors, Adrenergic, alpha-2, Adrenergic Uptake Inhibitors, Radiopharmaceuticals, Positron-Emission Tomography, Rats, Adrenergic alpha-2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Amphetamine Decreases 2C-Adrenoceptor Binding of [11C]ORM-13070: A PET Study in the Primate Brain. https://app.cochat.ai/papers/10.1093/ijnp/pyu081
- The paper
- Finnema, S. J., Hughes, Z. A., Haaparanta-Solin, M., Stepanov, V., Nakao, R., Varnas, K., Varrone, A., Arponen, E., Marjamaki, P., Pohjanoksa, K., Vuorilehto, L., Babalola, P. A., Solin, O., Grimwood, S., Sallinen, J., Farde, L., Scheinin, M., & Halldin, C. (2015). Amphetamine Decreases 2C-Adrenoceptor Binding of [11C]ORM-13070: A PET Study in the Primate Brain. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyu081
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.